Cetuximab plus TOFA (an allosteric inhibitor of ACC) exhibited significantly inhibitive effect on the growth of cetuximab-resistant HNSCC xenografts (Luo et al., 2017). The gene discussed is ACACA; the disease is head and neck squamous cell carcinoma.